Dec 28, 2023
Savara Introduced aPAP ClearPathTM to detect Autoimmune Pulmonary Alveolar Proteinosis On December 21, 2023, Savara, a clinical stage biopharmaceutical company launched aPAP ClearPathTM, which is used by the physicians to obtain a conclusive diagnosis of Autoimmune Pulmonary Alveolar Proteinosis (aPAP), a ...
Read More...
Jul 06, 2020
The Nontuberculous mycobacterial infection market worth is expected to grow at a CAGR of 6.6% by 2030 owing to robust NTM infection pipeline, rising prevalence among immunocompromised as well as immunocompetent populations, and a considerable shift towards branded therapeutics options. Planet Earth hosts a dive...
Read More...
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Newsletter/Whitepaper